Sequenta, Inc.’s Clonosight Test To Be Used By The Dana-Farber Cancer Institute/Acute Lymphoblastic Leukemia (ALL) Consortium

Published: Feb 25, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sequenta, Inc. today announced that the DFCI/ALL Consortium will utilize the ClonoSIGHT™ test, the first sequencing-based test for minimal residual disease (MRD) in lymphoid cancers, for clinical care of children with ALL.

Help employers find you! Check out all the jobs and post your resume.

Back to news